Back to dashboard
CommercialCoverageMedium impact

Dopamine Transporter Imaging with Single-Photon Emission Computed Tomography

Blue Cross & Blue Shield of Mississippi·MS · Nuclear Medicine, Neurology, Radiology·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBS Mississippi updated their policy for Dopamine Transporter Imaging with SPECT (DaT-SPECT), now covering it as medically necessary for clinically uncertain Parkinson disease and clinically uncertain dementia with Lewy bodies. All other indications remain investigational and non-covered.

Action Required

Action needed
Immediately: Update billing guidelines to ensure DaT-SPECT imaging is only billed for patients with clinically uncertain Parkinson disease or clinically uncertain dementia with Lewy bodies. Billing team must verify proper documentation of clinical uncertainty before submitting claims. Claims for other indications will be denied as investigational.